Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Equity Average (2019 - 2025)

Historic Equity Average for Takeda Pharmaceutical (TAK) over the last 8 years, with Q3 2025 value amounting to $47.9 billion.

  • Takeda Pharmaceutical's Equity Average changed N/A to $47.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $47.9 billion, marking a year-over-year change of. This contributed to the annual value of $48.0 billion for FY2025, which is 154.41% down from last year.
  • As of Q3 2025, Takeda Pharmaceutical's Equity Average stood at $47.9 billion.
  • In the past 5 years, Takeda Pharmaceutical's Equity Average registered a high of $49.7 billion during Q3 2023, and its lowest value of $45.9 billion during Q1 2023.
  • Over the past 5 years, Takeda Pharmaceutical's median Equity Average value was $47.9 billion (recorded in 2022), while the average stood at $47.9 billion.
  • Per our database at Business Quant, Takeda Pharmaceutical's Equity Average surged by 1182.79% in 2021 and then plummeted by 632.11% in 2025.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Equity Average stood at $47.6 billion in 2021, then fell by 3.09% to $46.2 billion in 2022, then rose by 2.44% to $47.3 billion in 2023, then increased by 4.87% to $49.6 billion in 2024, then fell by 3.36% to $47.9 billion in 2025.
  • Its Equity Average stands at $47.9 billion for Q3 2025, versus $46.5 billion for Q2 2025 and $47.1 billion for Q1 2025.